Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?

The reason why dopamine neurons die in Parkinson’s disease remains largely unknown. Emerging evidence points to a role for brain inflammation in neurodegeneration. Essential questions are whether brain inflammation happens sufficiently early so that interfering with this process can be expected to s...

Full description

Bibliographic Details
Main Author: Vidar Gundersen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Neuroscience
Subjects:
gut
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2020.580311/full
id doaj-a38cce1e477a4edcafbafcf34142dcfa
record_format Article
spelling doaj-a38cce1e477a4edcafbafcf34142dcfa2021-02-25T04:42:40ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-02-011410.3389/fnins.2020.580311580311Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?Vidar GundersenThe reason why dopamine neurons die in Parkinson’s disease remains largely unknown. Emerging evidence points to a role for brain inflammation in neurodegeneration. Essential questions are whether brain inflammation happens sufficiently early so that interfering with this process can be expected to slow down neuronal death and whether the contribution from inflammation is large enough so that anti-inflammatory agents can be expected to work. Here I discuss data from human PD studies indicating that brain inflammation is an early event in PD. I also discuss the role of T-lymphocytes and peripheral inflammation for neurodegeneration. I critically discuss the failure of clinical trials targeting inflammation in PD.https://www.frontiersin.org/articles/10.3389/fnins.2020.580311/fullmicrogliaalpha-synucleinT-cellsbraingutcervical lymph node
collection DOAJ
language English
format Article
sources DOAJ
author Vidar Gundersen
spellingShingle Vidar Gundersen
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Frontiers in Neuroscience
microglia
alpha-synuclein
T-cells
brain
gut
cervical lymph node
author_facet Vidar Gundersen
author_sort Vidar Gundersen
title Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
title_short Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
title_full Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
title_fullStr Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
title_full_unstemmed Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
title_sort parkinson’s disease: can targeting inflammation be an effective neuroprotective strategy?
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2021-02-01
description The reason why dopamine neurons die in Parkinson’s disease remains largely unknown. Emerging evidence points to a role for brain inflammation in neurodegeneration. Essential questions are whether brain inflammation happens sufficiently early so that interfering with this process can be expected to slow down neuronal death and whether the contribution from inflammation is large enough so that anti-inflammatory agents can be expected to work. Here I discuss data from human PD studies indicating that brain inflammation is an early event in PD. I also discuss the role of T-lymphocytes and peripheral inflammation for neurodegeneration. I critically discuss the failure of clinical trials targeting inflammation in PD.
topic microglia
alpha-synuclein
T-cells
brain
gut
cervical lymph node
url https://www.frontiersin.org/articles/10.3389/fnins.2020.580311/full
work_keys_str_mv AT vidargundersen parkinsonsdiseasecantargetinginflammationbeaneffectiveneuroprotectivestrategy
_version_ 1724252104913059840